SCHEMBL3399529

SCHEMBL3399529

C[C@@H]1CN[C@@H](C)CN1c1ccc(N)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.56
PIM1 P11309 1/20 0.37
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
TLR9 Q9NR96 4/20 0.37
TLR8 Q9NR97 4/20 0.37
TLR7 Q9NYK1 4/20 0.37
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
SIGMAR1 Q99720 2/20 0.33
ATR Q13535 1/20 0.33
ATRIP Q8WXE1 1/20 0.33
PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13746661 1.00 HDAC1 (0.56) HDAC1PIM1ROCK2ROCK1TLR9
SCHEMBL1108652 0.84 HDAC1 (0.51) HDAC1PIM1ROCK2ROCK1TLR9
SCHEMBL2178404 0.79 HDAC1 (0.47) HDAC1IRAK4
SCHEMBL3599737 0.79 HDAC1 (0.47) HDAC1TLR9TLR8TLR7
SCHEMBL1470706 0.79 HDAC1 (0.47) HDAC1IRAK4
SCHEMBL6859232 0.79 HDAC1 (0.47) HDAC1TLR9TLR8TLR7
SCHEMBL6859229 0.79 HDAC1 (0.47) HDAC1TLR9TLR8TLR7
SCHEMBL1470530 0.79 HDAC1 (0.47) HDAC1IRAK4
Hydrochloric Acid SCHEMBL1735168 0.78 HDAC1 (0.47) HDAC1IRAK4
SCHEMBL16853407 0.76 HDAC1 (0.39) HDAC1PIM1ROCK2ROCK1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 EP disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 HDAC1 1109/4885PIM1 184/4885ROCK2 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.